Steve Maarbani’s VentureCrowd is bringing a traditionally exclusive niche to the world of crowdfunding, launching a new diversified Health Tech Fund that aims to raise $10 million for investing in innovative companies he hopes could be the next Cochlear (ASX: COH).
Structured as an Early Stage Venture Capital Limited Partnership pending eligibility for a 10 per cent tax offset and tax-free returns for investors, the fund is targeting exits in three to five years with health, wellness and sustainability as central themes.
The fund will cover foodtech, medtech, biotech and digital health, building a diversified portfolio with first access to Gold Coast-based health-tech accelerator LuminaX for its April 2022 cohort of startups, as well as Uniseed, one of Australia’s longest running venture funds.
This article was originally posted on Business News Australia. Read the article in full on their website here.